Novel insulin/GIP co-producing cell lines provide unexpected insights into Gut K-cell function in vivo.
Enteroendocrine (EE) cells represent complex, rare, and diffusely-distributed intestinal epithelial cells making them difficult to study in vivo. A specific sub-population of EE cells called Gut K-cells produces and secretes glucose-dependent insulinotropic peptide (GIP), a hormone important for glucose homeostasis. The factors that regulate hormone production and secretion, as well as the timing of peptide release, are remarkably similar for K-cells and islet beta-cells suggesting engineering insulin production by K-cells is a potential gene therapeutic strategy to treat diabetes. K-cell lines could be used to study the feasibility of this potential therapy and to understand Gut K-cell physiology in general. Heterogeneous STC-1 cells were transfected with a plasmid (pGIP/Neo) encoding neomycin phosphotransferase, driven by the GIP promoter-only cells in which the GIP promoter was active survived genetic selection. Additional clones expressing pGIP/Neo plus a GIP promoter/insulin transgene were isolated-only doubly transfected cells produced preproinsulin mRNA. Bioactive insulin was stored and then released following stimulation with arginine, peptones, and bombesin-physiological GIP secretagogues. Like K-cells in vivo, the GIP/insulin-producing cells express the critical glucose sensing enzyme, glucokinase. However, glucose did not regulate insulin or GIP secretion or mRNA levels. Conversely, glyceraldehyde and methyl-pyruvate were secretagogues, indicating cells depolarized in response to changes in intracellular metabolite levels. Potassium channel opening drugs and sulphonylureas had little effect on insulin secretion by K-cells. The K-cell lines also express relatively low levels of Kir 6.1, Kir 6.2, SUR1, and SUR2 suggesting secretion is independent of K(ATP) channels. These results provided unexpected insights into K-cell physiology and our experimental strategy could be easily modified to isolate/characterize additional EE cell populations.
Ramshur
Erin B
EB
Department of Internal Medicine, Division of Metabolism, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Rull
Teena R
TR
Wice
Burton M
BM
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D019858:Enteroendocrine Cells / Q000187:drug effects / Q000502:physiology*; D005749:Gastric Inhibitory Polypeptide / Q000096:biosynthesis* / Q000235:genetics; D005941:Glucokinase / Q000378:metabolism; D005947:Glucose / Q000494:pharmacology; D007328:Insulin / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000502:physiology; D008564:Membrane Potentials; D051379:Mice; D010957:Plasmids / Q000235:genetics; D015221:Potassium Channels / Q000235:genetics / Q000378:metabolism; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014162:Transfection
D007328:Insulin; D015221:Potassium Channels; D012333:RNA, Messenger; D005749:Gastric Inhibitory Polypeptide; D000255:Adenosine Triphosphate; D005941:Glucokinase; D005947:Glucose